News & Events about Amicus Therapeutics Inc.
CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data CHMP Recommends Label for Long-Term Enzyme Replacement Therapy in Combination with Miglustat for both ERT-Experienced and Treatment-Nave Adults Living with Late-Onset Pompe Disease CHMP Opinion...
StockNews.com lowered shares of Amicus Therapeutics (NASDAQ:FOLD Get Rating) from a buy rating to a hold rating in a report released on Wednesday morning. Separately, Morgan Stanley upped their price target on Amicus Therapeutics from $14.00 to $15.00 and gave the stock an equal weight ...
Ticker Report
2 months ago
Amicus Therapeutics, Inc. (NASDAQ:FOLD Get Rating) Investment analysts at SVB Leerink reduced their Q4 2023 earnings per share (EPS) estimates for shares of Amicus Therapeutics in a note issued to investors on Monday, November 7th. SVB Leerink analyst J. Schwartz now expects that the...
Globe Newswire
3 months ago
PHILADELPHIA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided an EU regulatory update for AT-GAA. Earlier this morning, the Committee for...
Amicus Therapeutics, Inc. (NASDAQ:FOLD Get Rating) COO Bradley L. Campbell sold 16,410 shares of the firms stock in a transaction that occurred on Tuesday, June 21st. The stock was sold at an average price of $10.00, for a total transaction of $164,100.00. Following the transaction, ...